University of Oxford researchers are investigating whether combining different COVID-19 vaccines provides the same or better protection than one type of vaccine alone, Business Insider says.
Johnson & Johnson reports interim results from a Phase 1/2 study of its SARS-CoV-2 vaccine in the New England Journal of Medicine, according to Bloomberg.
The drugmaker is supporting access to NGS testing in these countries to identify lung and pancreatic cancer patients with NRG1 fusions who can join its study.
The test, called LifeKit Prevent, analyzes microbial genomic biomarkers in stool samples that are strongly associated with specific stages of CRC progression.
Early trial data of a Sanofi and GlaxoSmithKline SARS-CoV-2 vaccine indicates an insufficient immune response among older participants, according to Reuters.